Zacks: Analysts Set $28.00 Price Target for Bio-Path Holdings Inc (NASDAQ:BPTH)
Bio-Path Holdings Inc (NASDAQ:BPTH) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $28.00 for the company and are predicting that the company will post ($0.60) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Bio-Path an industry rank of 87 out of 256 based on the ratings given to related companies.
Separately, HC Wainwright restated a “buy” rating on shares of NioCorp Developments in a research note on Tuesday, July 16th.
Shares of Bio-Path stock traded up $0.13 on Wednesday, hitting $13.85. The stock had a trading volume of 900 shares, compared to its average volume of 282,221. Bio-Path has a one year low of $1.61 and a one year high of $73.52. The firm has a market cap of $39.42 million, a PE ratio of -0.97 and a beta of 3.25. The firm has a 50-day moving average of $13.54.
Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.89) earnings per share (EPS) for the quarter. As a group, analysts expect that Bio-Path will post -3.08 EPS for the current fiscal year.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also: How Do Mutual Funds Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.